Adebrelimab, apatinib, and liposomal irinotecan for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (adebrelimab, apatinib, and liposomal irinotecan) for people with advanced gastric or gastroesophageal junction cancer whose first treatment stopped working. The goal is to see if this new combination can help when standard options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced gastric or gastroesophageal junction adenocarcinoma that got worse after one prior treatment, including immunotherapy that worked for at least 7 months.
- Your cancer has at least one measurable tumor that hasn't been treated with radiation (unless it has grown after radiation).
- You are in good general health (ECOG score 0 or 1) and expected to live at least 12 weeks.
- Your blood counts, liver, and kidney function are within certain safe limits (absolute neutrophil count at least 1.5, platelets at least 100, hemoglobin at least 90, bilirubin and liver enzymes not too high, creatinine clearance at least 60).
- Your cancer does not have HER2 protein (HER2 negative).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liposomal irinotecan and albumin-bound paclitaxel for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after first-line chemotherapy. It may be an option if you have already tried a fluorouracil-based treatment.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.